Heparin-Induced Thrombocytopenia

Pharmacology in the Catheterization Laboratory

Volumn , Issue , 2009, Pages 261-269

  Cruz Gonzalez, Ignacio ^a,b   Sanchez Ledesma, Maria ^b   Jang, Ik Kyung ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

"4 T's" assessment point system for patients with suspected HIT; Anticoagulation anomalies; Antigenic and functional tests for heparin PF4 antibodies; Argatroban alternative anticoagulant; Chronic anticoagulation; College of American Pathologists recommending heparin PF4 antibody testing for patients with HIT; Heparin commonly used anticoagulant; Heparin induced thrombocytopenia (HIT); HIT and antibodies, IgG; thrombocytopenia of HIT moderate in severity

Indexed keywords

EID: 84889427718     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444306347.ch35     Document Type: Chapter

References (47)

1. Fahey VA. Heparin-induced thrombocytopenia. J Vasc Nurs. 1995;467(13):112-116.
2. Campbell KR, Mahaffey KW, Lewis BF, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasc Cardiol. 2000;12:14-19.
3. Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparininduced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol. 1989;73:235-240.
4. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin induced. Blood. 1994;84:3691-3699.
5. Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin 8. Blood. 2001;98:1252-1254.
6. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med. 1987;316:581-589.
7. Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin induced thrombocytopenia. Blood. 2000;96:1703-1708.
8. Mattioli AV, Bonetti L, Sternieri S, Mattioli G. Heparininduced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital Heart J. 2000;1:39-42.
9. Verma AK, Levine M, Shalansky SJ, Carter CJ, Kelton JG. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy. 2003;23:745-753.
10. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparininduced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003;101:2955-2959.
11. Yamamoto S, Koide M, Matsuo M, et al. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis. 1996;28:82-85.
12. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and lowmolecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106:2710-2715.
13. Shuster TA, Silliman WR, Coats RD, Mureebe L, Silver D. Heparin induced thrombocytopenia: twenty-nine years later. J Vasc Surg. 2003;38:1316-1322.
14. Matsuo T, Tomaru T, Kario K, Hirokawa T, HIT Research Group of Japan. Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute coronary syndrome. Thromb Res. 2005;115:475-481.
15. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:311-337.
16. Warkentin TE, Levine MN, Hirsh J, et al. Heparininduced thrombocytopenia in patients treated with lowmolecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:13301335.
17. Warkentin TE, Kelton JG. Delayed-onset heparininduced thrombocytopenia and thrombosis. Ann Intern Med. 2001;135:502-506.
18. Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost. 1977;3:160-174.
19. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163:1849-1856.
20. Hirsh J, Heddle N, Kelton JG. Treatment of heparininduced thrombocytopenia: a critical review. Arch Intern Med. 2004;164:361-369.
21. Chong BH, Gallus AS, Cade JF, et al. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis. Thromb Haemost. 2001;86:1170-1175.
22. Warkentin TE. Heparin-induced skin lesions. Br J Haematol. 1996;92:494-497.
23. Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipidsyndrome. Hematology (Am Soc Hematol Educ Prog). 2003;1:497-519.
24. Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation. 2005;111:2671-2683.
25. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia: recommendations of the College of American Pathologists. Arch Pathol Lab Med. 2002;126:1415-1423.
26. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99:73-80.
27. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation. 1999;100:587-593.
28. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparininduced thrombocytopenia. Curr Hematol Rep. 2003;2:148-157.
29. Tomer A. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol. 1997;98:648-656.
30. Pouplard C, Amiral J, Borg J-Y, Laporte-Simitsidis S, Delahousse B, Gruel Y. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1999;111:700-706.
31. Lewis BE, Matthai WH, Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet Cardiovasc Interv. 2002;57:177-184.
32. Jang IK, Lewis BE, Matthai WH, Kleiman NS. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonran-domized pilot study. J Thromb Thrombolysis. 2004;18:31-37.
33. Mahaffey KW, Lewis BE, Wildermann NM, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol. 2003;15:611-616.
34. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142:952-959.
35. Pinto DS, Sperling RT, Tu RM, Cohen DJ, Carrozza JP. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronaryintervention in patients with heparin-induced thrombocytopenia. Cathet Cardiovasc Interv. 2003;58:65-68.
36. Manfredi JA, Wall RP, Sane DC, Braden GA. Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombo cytopenia undergoing percutaneous coronary intervention: case reports. Cathet Cardiovasc Interv. 2001;52:468-472.
37. Greinacher A, Warkentin TE. Treatment of heparininduced thrombo-cytopenia: an overview. In: Warketin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 3rd ed. New York, NY: Marcel Dekker;2004:335-370.
38. Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost. 2005;11:279-287.
39. Gosselin RC, Dager WE, King JH, et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol. 2004;121:593-599.
40. Harder S, Graff J, Klinkhardt U, et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on pro-thrombin time, activated partial thromboplastin time, and ecarin clotting time. Thromb Haemost. 2004;91:1137-1145.
41. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000;20:318-329.
42. Vanholder R, Camez A, Veys N, Van Loo A, Dhondt AM, Rignoir S. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost. 1997;77:650-655.
43. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost. 1993;69:157-163.
44. Fischer KG. Hirudin in renal insufficiency. Semin Thromb Hemost. 2002;28:467-482.
45. Murray PM, Reddy BV, Grossman EJ, et al. A prospective comparison of three argatroban treatment regimens during in end-stage renal disease. Kidney Int. 2004;66:2446-2453.
46. Stratmann G, DiSilva AM, Tseng EE, et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg. 2004;98:1635-1639.
47. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292.